Active Release Mechanism of the Gibco CTS Detachable Dynabeads Beads

Understanding Detachable Dynabeads

If you work in the cell therapy field, you are probably familiar with Gibco CTS Dynabeads products. As of 2023, they are used in more than 200 active clinical trials and several commercialized therapies on the market. The next generation of CTS Dynabeads products has just entered the market. The Gibco CTS Detachable Dynabeads CD3/CD28 Kit provides the same one-step isolation and activation as our legacy Dynabeads kits with a major difference—it enables the active release of CTS Dynabeads magnetic beads from the target cells at any point in the process.

The CTS Detachable Dynabeads magnetic beads are based on our existing paramagnetic bead technology but conjugated to highly specific, single-domain VHH antibodies that target specific clusters of differentiation (CD) markers for isolation and/or activation. Each kit comes with an active release buffer enclosed in a CTS DynaCellect Magnetic Separation System-compatible bioprocess container. After the isolation of target immune cells and magnetic separation in the CTS DynaCellect system, the release buffer allows you to actively detach target cells from the CTS Dynabeads magnetic beads through a competitive binding mechanism.

Curious how this works? Watch the video below to learn how the first GMP active release mechanism of its kind works for GMP, clinical trials, and commercial manufacturing use.

What does this active detachment mean for you and for therapeutic development?

This flexible technology provides an opportunity for you to optimize isolation, activation, purity, yield, cell viability, and desired phenotype in your process. It also enables process improvements such as:

• Increased control over target cell isolation and bead removal steps to help you streamline your overall process
• Increased control over cell activation and persistence of activation signals post-isolation
• High levels of pure T-cells free from ancillary material
• Optimal recovery of target cells
• Desired cell phenotypes for downstream gene modification and fold expansion

Perhaps what matters the most is what this new technology means to therapeutic development. Being able to release the Dynabeads from target cells at any time actively helps preserve the early memory T-cell phenotype upstream in the process. Research has shown that less differentiated cells—young naïve (T_N) cells that differentiate into central memory (T_CM) cells and finally mature into T-effector memory (T_EM) and T-effector (T_EFF) cells—correlate with higher efficacy of T-cell therapies. Actively releasing magnetic beads from cells can help you obtain naïve and early memory cell phenotypes by controlling the duration of activation. And, of course, releasing the Dynabeads magnetic beads sooner may help shorten the manufacturing process so patients can get their therapy sooner.

This is just the first in a line of new innovations to launch within the same CTS Detachable Dynabeads platform.

Related resources

• Flyer: Meet the next generation of CTS Dynabeads magnetic beads
• Flyer: CTS Detachable Dynabeads CD3/CD28 Kit

To see more of Thermo Fisher Scientific’s bioprocessing innovations in cell therapy, check out our Gibco Cell Therapy Bioprocessing Solutions.

For Research Use or Manufacturing of Cell, Gene, or Tissue-Based Products. CAUTION: Not intended for direct administration into humans or animals